← Back to Home

Phase 3 Trial of Maintenance Therapy for Small Cell Lung Cancer: Two-Drug Combination Extends Survival but Increases Severe Side Effects

Among patients whose disease had not progressed after initial chemotherapy and immunotherapy, tarlatamab plus durvalumab reduced the relative risk of death by 58%. This provides strong evidence for extending disease control, but survival data remain immature, and the treatment burden must also be weighed.

By SURL BioNews

For patients with extensive-stage small cell lung cancer, an important treatment challenge is how to sustain disease control after initial therapy. The phase 3 DeLLphi-305 trial now provides new evidence: adding tarlatamab, which engages T cells to attack cancer cells, during maintenance therapy extended overall survival compared with durvalumab alone. The results were presented on October 24 at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.

This international, open-label, randomized trial enrolled 563 participants at 175 trial sites in 29 countries. All patients had received initial treatment with durvalumab plus platinum-based chemotherapy and etoposide, and their disease had not progressed before they were assigned to receive either the two-drug combination or single-agent maintenance therapy. These results therefore address how to continue treatment after initial therapy, and their applicability is based on this patient population.

tarlatamab (brand name Imdelltra) is a bispecific T-cell engager therapy. One end recognizes the DLL3 protein on small cell lung cancer cells, while the other binds to CD3 on T cells, bringing immune cells and cancer cells together to promote an attack. Dana-Farber Cancer Institute noted that the drug is already approved in the United States for later-line treatment; this trial moved it into the earlier maintenance setting in combination with durvalumab (brand name Imfinzi).

In the prespecified interim analysis, with a median follow-up of approximately 16 months, estimated median overall survival was 21.1 months in the combination group and 12.7 months in the single-agent group. The hazard ratio for death was 0.42, with a 95% confidence interval of 0.32 to 0.54, reaching statistical significance. The reported 58% reduction in the risk of death refers to the relative difference in risk during follow-up; it does not mean that every patient gains the same amount of additional life. One-year survival rates were approximately 79% and 53%, respectively.

Disease control also differed: median progression-free survival was 7.4 months, compared with 1.9 months in the control group. Both Dana-Farber and conference coverage noted that survival outcomes also favored the combination among patients with brain or liver metastases. The trial allowed patients with asymptomatic brain metastases, whether treated or untreated, to participate, extending the evidence to some clinically challenging situations. However, subgroup results still need to be interpreted in the context of the overall trial size.

The improvement in efficacy came with more side effects. According to OncLive's summary, grade 3 or higher treatment-related adverse events occurred in 20.9% of the combination group and 10.8% of the single-agent group. Cytokine release syndrome occurred in 49.6% of the combination group, mostly at grade 1 or 2, with one grade 3 event and no grade 4 or fatal cases. No treatment-related deaths were reported in the combination group either. These findings indicate that, even though most of these immune reactions were mild, treatment still requires appropriate monitoring and management capabilities.

This study provides strong evidence to support a change in maintenance therapy, but its long-term benefits are not yet established. CancerNetwork reported that the investigators emphasized that overall survival data remain immature, and further follow-up could change the current median estimates. The trial also did not include patients whose disease progressed during initial treatment. Longer-term survival and safety follow-up, along with regulatory review of this use, will determine how the combination enters routine care.

References

  1. Amgen
  2. Dana-Farber Cancer Institute
  3. OncLive
  4. CancerNetwork